The beneficial effects of beta-interferon on relapse-related outcomes (i.e., relapse rates) were shown in people with SPMS [289–292], while one out of the five studies found beneficial effects on short-term disability progression outcomes [288, 289]. Here, IFNB1 is linked to secondary progressive multiple sclerosis.